COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #134 of 260
9/9 Early, Late
Kirenga et al., BMJ Open Respiratory Research, doi:10.1136/bmjresp-2020-000646 (Peer Reviewed)
Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda
Source   PDF   Share   Tweet
Prospective 56 patients in Uganda, 29 HCQ and 27 control, showing 25.6% faster recovery with HCQ, 6.4 vs. 8.6 days (p = 0.20). There was no ICU admission, mechanical ventilation, or death.
Treatment delay is not specified but at least a portion of patients appear to have been treated early.

Kirenga et al., 9/9/2020, prospective, Uganda, Africa, peer-reviewed, 29 authors, dosage not specified.
median time to recovery, 25.6% lower, relative time 0.74, p = 0.20, treatment 29, control 27.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit